Overview

Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization. Dexamethasone is a medication that may decrease hospitalization time for people with ACS, but it may also bring about new sickle cell pain. This study will evaluate the effectiveness of a dexamethasone regimen that includes a gradual dose reduction at decreasing hospitalization and recovery time in people with SCD and ACS.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate